EXCLUSIVE: Scienture Expands Coverage For Opioid Overdose Treatment Ahead Of Commercial Launch

Scienture Holdings Inc. (NASDAQ:SCNX) said Tuesday that its opioid overdose attraction Rezenopy (naloxone HCl) Nasal Spray 10 mg has been added to the formulary of a ample nationalist wellness plan, broadening commercialized and Medicare supplemental sum up of the product’s planned mid-July 2026 launch.

Rezenopy Coverage Extends To More Than 100 Million Lives

The institution said the summation increases imaginable entree to much than 100 cardinal covered lives crossed the U.S., marking different measurement successful its commercialization strategy for the naloxone product.

Rezenopy is the highest FDA-approved naloxone dose per nasal spray disposable successful the U.S. The single-use nasal spray delivers 10 mg of naloxone hydrochloride and is intended for the exigency attraction of known oregon suspected opioid overdose.

According to information cited by Scienture from IQVIA for the 12 months ended April 2026, yearly U.S. naloxone income totaled astir $144 million, with portion measurement reaching 9.8 cardinal units.

Read Also: EXCLUSIVE: Penny Stock Scienture Reports Revenue Surge, Expanding Market Access In 2025

Commercial Rollout Gains Momentum For Scienture

Scienture said it is pursuing a multi-channel commercialization strategy targeting institutional, government, and commercialized customers.

To enactment the nationwide launch, the institution precocious expanded its commercialized enactment by adding 3 income representatives focused connected driving adoption crossed organization and commercialized markets.

The latest sum enlargement follows antecedently announced Group Purchasing Organization agreements secured successful March 2026.

Scienture said those agreements supply commercialized entree for Rezenopy crossed much than 5,000 healthcare facilities and make the imaginable to scope implicit 60% of the U.S. organization naloxone market.

Scienture Executives Highlight Market Opportunity

Executive Chairman and co-CEO Shankar Hariharan said the merchandise enters a ample and expanding naloxone marketplace with a differentiated illustration arsenic the highest FDA-approved naloxone dose per nasal spray disposable successful the country.

In January, the United States Patent and Trademark Office issued a U.S. Patent, an Orange Book-listable patent covering Rezenopy (naloxone HCl) Nasal Spray 10 mg.

The institution said the patent is effectual January 6, 2026, with an expiry day of February 5, 2041.

SCNX Stock Price Activity: Scienture shares were down 0.28% astatine $0.35 during premarket trading connected Tuesday, according to Benzinga Pro data.

Photo via Shutterstock

Up Next: Transform your trading with Benzinga Edge's one-of-a-kind marketplace commercialized ideas and tools. Click present to entree unsocial insights that tin acceptable you up successful today's competitory market.